Quratis Inc.
Founded in 2016 and KOSDAQ-listed since 2023, Quratis develops tuberculosis, schistosomiasis, and COVID-19 vaccines and runs a CDMO plant.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureQuratis was founded in 2016 and listed on KOSDAQ in 2023 as a vaccine developer. It develops tuberculosis vaccine QTP101, schistosomiasis vaccine QTP105, and mRNA COVID-19 vaccine QTP104, using recombinant protein and repRNA platforms with the GLA-SE adjuvant. Its Osong plant makes 50 million vials yearly, backed by deals with IDRI, HDT Bio, PAI Life Sciences, and China's Lukang Pharmaceutical.
Products & technology
- QTP101Tuberculosis vaccine for BCG-vaccinated adults/adolescents and adults aged 55-74
- QTP105Schistosomiasis vaccine
- QTP104Next-generation mRNA COVID-19 vaccine
Regulatory approvals
data.go.kr1 Korean MFDS drug approvals · 2022
- MFDS drugQuaC inj.2022-01-12Drug · Prescription · Notification202200217
Clinical trials
data.go.kr5 MFDS clinical trial authorisations · 2017–2024 (Phase 1 3 · Phase 2b/3 1 · Phase 2 1)
- Phase 1QTP1012024-03-14
7 trial sites
- Phase 2b/3QTP1012022-07-21
5 trial sites
- Phase 1QTP1042021-07-19
5 trial sites
- Phase 1QTP1012018-12-11
1 trial site
- Phase 2QTP1012017-12-19
3 trial sites
R&D and key agreements
Source: DART corporate disclosureQTP101 · 결핵 예방 · 임상 2b/3상 (국내 IND 승인, 필리핀 PFDA 신청) · Completed Phase 1 in the US, Phase 1b/2a in South Africa, and Phase 2a (adult)/Phase 1 (adolescent) trials in Korea; IRB approvals obtained from 5 Korean institutions between May 27 and Sep 25, 2024 for the multinational Phase 2b/3 trial
QTP105 · 주혈흡충증 예방 · 임상 1b상 · Licensed from PAI Life Sciences
QTP104 · 코로나19 예방 · 임상 1상 종료 · Co-developed with HDT Bio
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition